Comparing Tegoprazan and Lansoprazole for Treating Bleeding Peptic Ulcers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to compare the effectiveness of tegoprazan versus lansoprazole in healing bleeding peptic ulcers in patients from the Indonesian population. Participants will be randomly assigned to receive either tegoprazan 50 mg or lansoprazole 30 mg daily for two weeks, with endoscopic examinations conducted before and after treatment to assess healing rates. The study will also monitor the safety and occurrence of adverse effects associated with both medications.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Subjects diagnosed with upper gastrointestinal bleeding caused by peptic ulcer through gastroscopic examination

Exclusion Criteria:

* Allergic to Tegoprazan or Lansoprazole
* Diagnosed with gastric or duodenal cancer, pregnant
* History of H. pylori infection treatment failure
* Presence of comorbidities such as chronic kidney disease or decompensated liver cirrhosis
* Alcohol consumption
* Undergoing chemotherapy

Where it's running

• Cipto Mangunkusumo National General Hospital
  Jakarta, DKI Jakarta, Indonesia Recruiting
• Atma Jaya Hospital
  Jakarta, DKI Jakarta, Indonesia Recruiting

Study contacts

• Study coordinator: Mario Steffanus MD
• Email: mario.steffanus@atmajaya.ac.id
• Phone: +6281288002263

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Tegoprazan vs Lansoprazole for Healing Bleeding Peptic Ulcers

  This trial tests whether tegoprazan heals bleeding peptic ulcers faster than lansoprazole over 14 days in adults with upper GI bleeding in Indonesia.

  Recruiting at 3 sites Phase 2 Universitas Indonesia · Tangerang, Banten and 2 other locations · NCT07708545

• Sepsis Chart Implementation and 7-Day Mortality in Indonesian Hospitals

  This study tests whether using a paper-based sepsis chart helps doctors treat sepsis faster and see if it lowers 7-day deaths for adults in two Jakarta hospitals.

  Recruiting Dr Cipto Mangunkusumo General Hospital · Jakarta Pusat, DKI Jakarta and 1 other locations · NCT07843277

• Molecular tests to speed up sepsis microbe ID at Indonesia’s national referral hospital

  This study tests whether Hybrispot DNA Flow and metagenomic sequencing can identify sepsis-causing microbes faster than standard blood culture in adult patients at a major Indonesian hospital.

  Recruiting Dr Cipto Mangunkusumo General Hospital · Jakarta, DKI Jakarta · NCT07841535

• Umbilical cord stem cells added during Kasai to help biliary atresia

  This early-stage trial tests whether injecting umbilical cord mesenchymal stem cells during Kasai portoenterostomy is safe and helpful for infants with biliary atresia.

  Recruiting Phase 1 Dr Cipto Mangunkusumo General Hospital · Jakarta Pusat, DKI Jakarta · NCT07797673

• Using natural killer cell therapy to treat liver cancer

  This study is testing a new therapy using natural killer cells to see if it can help people with liver cancer feel better and live longer.

  Recruiting Phase 1 Dr Cipto Mangunkusumo General Hospital · Jakarta Pusat, Jakarta Special Capital Region · NCT06044506

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.